For the second time in a month, Pozen (Nasdq: POZN) is involved in the termination of a drug partnership. The latest involves a distribution deal for a pain reliever in South America.

Pozen made the announcement through an SEC filing on Monday, noting the termination of the deal with Johnson & Johnson’s Cilag GmbH International, took effect on Dec. 22.

Pozen’s stock tumbled earlier this month with the termination of a drug development deal with Sanofi.

There was “no dispute” between Pozen and Cilag, Pozen said in the filing.

The filing reads:

“On December 22, 2014, POZEN Inc., a Delaware corporation (“POZEN”), entered into a mutual termination letter (the “Termination Letter”) with Cilag GmbH International (“Cilag”), a division of Johnson & Johnson, terminating that certain License Agreement (the “Agreement”) dated as of March 21, 2011, for the exclusive development and commercialization of MT 400 in Brazil, Colombia, Ecuador and Peru. MT 400 is POZEN’s proprietary combination of sumatriptan and naproxen sodium, a multiple mechanism triptan therapy for the treatment of acute migraine.

“Although there is no dispute between the parties regarding the Agreement, the parties have mutually agreed to terminate the Agreement. As a result, the Agreement will terminate, in accordance with the terms of the Termination Letter, on January 21, 2015, thirty (30) days after signature of the Termination Letter by both parties. Under the terms of the Termination Letter, at POZEN’s request, which can be made at any time within two years from the effective date of the Termination Letter, the parties will negotiate in good faith commercially reasonable terms of a supply agreement whereby Cilag would supply POZEN, or its licensees, with MT400 for a period equal to the shorter of (i) two (2) years, or (ii) POZEN’s establishment of an alternative supplier. The Termination Letter provides a mutual release by the parties from any claims arising out of or relating to the Agreement. POZEN will recognize approximately $257,300 in licensing revenue in the fourth quarter of fiscal year 2014 as a result of this termination.”